Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


27.08.2018

1 Ann Oncol
1 Arch Bronconeumol
1 Arch Pathol Lab Med
3 BMC Cancer
1 Cancer
1 Cancer Res
1 Clin Lung Cancer
1 Eur Respir J
3 Int J Oncol
1 J Thorac Oncol
5 Oncol Rep
2 Oncologist
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. THOMAS M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, et al
    Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study.
    Ann Oncol. 2018 Aug 20. pii: 5076437. doi: 10.1093.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  2. BENITO BERNALDEZ C, Almadana Pacheco V
    Spontaneous Regression of Pulmonary Emphysematous Bulla.
    Arch Bronconeumol. 2016 Nov 1. pii: S0300-2896(16)30231.
    PubMed     Text format    


    Arch Pathol Lab Med

  3. AKALIN A, Ergin A, Remiszewski S, Mu X, et al
    Resolving Interobserver Discrepancies in Lung Cancer Diagnoses by Spectral Histopathology.
    Arch Pathol Lab Med. 2018 Aug 24. doi: 10.5858/arpa.2017-0476.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. KIM Y, Pierce CM, Robinson LA
    Impact of viral presence in tumor on gene expression in non-small cell lung cancer.
    BMC Cancer. 2018;18:843.
    PubMed     Text format     Abstract available

  5. MERVAI Z, Egedi K, Kovalszky I, Baghy K, et al
    Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.
    BMC Cancer. 2018;18:157.
    PubMed     Text format     Abstract available

  6. SCHUETTE W, Schirmacher P, Eberhardt WEE, Dietel M, et al
    Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    BMC Cancer. 2018;18:135.
    PubMed     Text format     Abstract available


    Cancer


  7. Neoadjuvant Nivolumab Safe, Led to Major Response Rates in Resectable Lung Cancer.
    Cancer. 2018;124:3283.
    PubMed     Text format    


    Cancer Res

  8. ZHOU Y, Shurin GV, Zhong H, Bunimovich YL, et al
    Schwann cells augment cell spreading and metastasis of lung cancer.
    Cancer Res. 2018 Aug 22. pii: 0008-5472.CAN-18-1702.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  9. CUMMINGS MA, Ma SJ, Hermann G, Serra L, et al
    Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis.
    Clin Lung Cancer. 2018 Jul 30. pii: S1525-7304(18)30190.
    PubMed     Text format     Abstract available


    Eur Respir J

  10. VISSER S, Huisbrink J, van 't Veer NE, van Toor JJ, et al
    Renal impairment during pemetrexed maintenance in patients with advanced non-small-cell lung cancer: a cohort study.
    Eur Respir J. 2018 Aug 23. pii: 13993003.00884-2018.
    PubMed     Text format     Abstract available


    Int J Oncol

  11. LI W, Shi Y, Wang R, Pan L, et al
    Resveratrol promotes the sensitivity of small-cell lung cancer H446 cells to cisplatin by regulating intrinsic apoptosis.
    Int J Oncol. 2018 Aug 21. doi: 10.3892/ijo.2018.4533.
    PubMed     Text format     Abstract available

  12. YOU C, Zhang S, Sun Y, Zhang S, et al
    beta-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors.
    Int J Oncol. 2018 Aug 21. doi: 10.3892/ijo.2018.4529.
    PubMed     Text format     Abstract available

  13. LI YJ, Sun YX, Hao RM, Wu P, et al
    miR-33a-5p enhances the sensitivity of lung adenocarcinoma cells to celastrol by regulating mTOR signaling.
    Int J Oncol. 2018;52:1328-1338.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  14. BORGHAEI H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, et al
    24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Aug 20. pii: S1556-0864(18)30942.
    PubMed     Text format     Abstract available


    Oncol Rep

  15. HUANG F, Chen J, Wang Z, Lan R, et al
    delta-Catenin promotes tumorigenesis and metastasis of lung adenocarcinoma.
    Oncol Rep. 2018;39:809-817.
    PubMed     Text format     Abstract available

  16. ZHOU J, Hu Q, Zhang X, Zheng J, et al
    Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Oncol Rep. 2018;39:1783-1792.
    PubMed     Text format     Abstract available

  17. OH YJ, Park SY, Seo YH
    The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oncol Rep. 2018;39:1775-1782.
    PubMed     Text format     Abstract available

  18. LIU KT, Yeh IJ, Chou SK, Yen MC, et al
    Regulatory mechanism of fatty acidCoA metabolic enzymes under endoplasmic reticulum stress in lung cancer.
    Oncol Rep. 2018 Aug 21. doi: 10.3892/or.2018.6664.
    PubMed     Text format     Abstract available

  19. HU P, Wong PT, Zhou Q, Sheng L, et al
    Clinical relevance of the multidrug resistanceassociated protein 1 gene in nonsmall cell lung cancer: A systematic review and metaanalysis.
    Oncol Rep. 2018 Aug 17. doi: 10.3892/or.2018.6652.
    PubMed     Text format     Abstract available


    Oncologist

  20. BUTTIGLIERO C, Shepherd FA, Barlesi F, Schwartz B, et al
    Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2018 Aug 23. pii: theoncologist.2018-0089.
    PubMed     Text format     Abstract available

  21. XIE L, Nagpal S, Wakelee HA, Li G, et al
    Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
    Oncologist. 2018 Aug 20. pii: theoncologist.2018-0264.
    PubMed     Text format     Abstract available


    PLoS One

  22. CHEN X, Yang Y, Katz SI
    Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
    PLoS One. 2018;13:e0202384.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: